GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data
This article was originally published in The Pink Sheet Daily
Executive Summary
GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.
You may also be interested in...
Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
For GlobeImmune, the pharmacogenomic implications are important not only as a predictor of response to interferon, but also as a predictor of how the GI-5005 vaccine behaves. The company is tailoring its Phase III approach using that information.
Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
For GlobeImmune, the pharmacogenomic implications are important not only as a predictor of response to interferon, but also as a predictor of how the GI-5005 vaccine behaves. The company is tailoring its Phase III approach using that information.
Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis
Positive Phase II results for GlobeImmune's immune-boosting hepatitis C vaccine GI-5005 were underscored at the European Association for the Study of the Liver meeting in Vienna April 17 by results from a newly available biomarker test that shows the therapy is most effective at clearing the virus from patients whose genetic status predicts little chance for complete recovery